BethanyBDavisMD

Clinical Trials

• CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia Start of enrollment: 2021 Jun 18

  Active, not recruiting

  Phase 3

• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) Start of enrollment: 2021 Jun 02

  Active, not recruiting

  Phase 3

• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Start of enrollment: 2021 Nov 12

  Recruiting

  Phase 3

• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Start of enrollment: 2022 Mar 07

  Enrolling by invitation

  Phase 3

• Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Start of enrollment: 2017 Jan 01

  Active, not recruiting

  Phase 3

• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Start of enrollment: 2018 Dec 14

  Completed

  Phase 3

• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Start of enrollment: 2017 Jun 15

  Completed

  Phase 3

• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features Start of enrollment: 2018 Jun 15

  Completed

  Phase 3

• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia Start of enrollment: 2019 Feb 15

  Terminated

  Phase 2, Phase 3

• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia Start of enrollment: 2019 Apr 15

  Completed

  Phase 2

• Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo Start of enrollment: 2019 Dec 14

  Completed

  Phase 2

• A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Start of enrollment: 2022 Jun 30

  Recruiting

  Phase 2

• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia Start of enrollment: 2022 Sep 02

  Recruiting

  Phase 2

• Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Start of enrollment: 2021 Sep 30

  Active, not recruiting

  Phase 3

• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Start of enrollment: 2021 Oct 08

  Enrolling by invitation

  Phase 3

• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Start of enrollment: 2020 Sep 15

  Terminated

  Phase 3

• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Start of enrollment: 2020 Sep 15

  Completed

  Phase 3

• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Start of enrollment: 2023 Jan 05

  Terminated

  Phase 3

• Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD Start of enrollment: 2019 Oct 17

  Completed

  Phase 3

• A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder Start of enrollment: 2018 Nov 19

  Completed

  Phase 3

• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. Start of enrollment: 2019 Nov 15

  Completed

  Phase 3

• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia Start of enrollment: 2018 Jul 30

  Terminated

  Phase 3

• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® Start of enrollment: 2019 Apr 29

  Terminated

  Phase 3

• Join now to see all